OrthoPediatrics (KIDS) Expected to Announce Quarterly Earnings on Wednesday

OrthoPediatrics (NASDAQ:KIDS - Get Free Report) is expected to post its Q1 2025 quarterly earnings results after the market closes on Wednesday, May 7th. Analysts expect the company to announce earnings of ($0.38) per share and revenue of $51.68 million for the quarter. OrthoPediatrics has set its FY 2025 guidance at EPS.

OrthoPediatrics (NASDAQ:KIDS - Get Free Report) last announced its quarterly earnings data on Tuesday, March 4th. The company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.04. OrthoPediatrics had a negative return on equity of 5.78% and a negative net margin of 15.00%. The company had revenue of $52.67 million during the quarter, compared to analysts' expectations of $51.16 million. During the same quarter last year, the company earned ($0.23) EPS. On average, analysts expect OrthoPediatrics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

OrthoPediatrics Stock Down 3.0 %

KIDS traded down $0.64 on Monday, hitting $20.77. 12,944 shares of the company were exchanged, compared to its average volume of 197,636. The stock's fifty day moving average is $23.18 and its 200-day moving average is $24.22. OrthoPediatrics has a 12 month low of $20.25 and a 12 month high of $35.99. The company has a debt-to-equity ratio of 0.19, a quick ratio of 3.68 and a current ratio of 7.17. The company has a market cap of $504.32 million, a PE ratio of -16.81 and a beta of 1.09.

Analyst Ratings Changes

Several research firms have recently commented on KIDS. Needham & Company LLC reissued a "buy" rating and issued a $42.00 price objective on shares of OrthoPediatrics in a report on Wednesday, April 9th. Truist Financial cut their price target on shares of OrthoPediatrics from $26.00 to $24.00 and set a "hold" rating for the company in a research note on Friday, April 11th. Lake Street Capital began coverage on shares of OrthoPediatrics in a report on Monday, April 7th. They issued a "buy" rating and a $37.00 target price on the stock. Finally, Stifel Nicolaus cut their target price on shares of OrthoPediatrics from $40.00 to $32.00 and set a "buy" rating for the company in a research note on Wednesday, March 5th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $37.00.

Insider Activity

In other OrthoPediatrics news, CEO David R. Bailey sold 6,620 shares of the stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $24.86, for a total value of $164,573.20. Following the transaction, the chief executive officer now directly owns 319,155 shares of the company's stock, valued at $7,934,193.30. This represents a 2.03 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, General Counsel Daniel J. Gerritzen sold 5,310 shares of the firm's stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $24.86, for a total transaction of $132,006.60. Following the sale, the general counsel now owns 110,767 shares of the company's stock, valued at $2,753,667.62. This trade represents a 4.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 23,732 shares of company stock valued at $589,978 over the last ninety days. 32.70% of the stock is currently owned by company insiders.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.